Phase II Study of Interleukin 6 Blockade With Siltuximab to Decrease Symptom Burden in Patients Age 60-75 Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma and AL Amyloidosis

Trial Profile

Phase II Study of Interleukin 6 Blockade With Siltuximab to Decrease Symptom Burden in Patients Age 60-75 Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma and AL Amyloidosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Mar 2018

At a glance

  • Drugs Siltuximab (Primary)
  • Indications Amyloid light-chain amyloidosis; Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Mar 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
    • 14 Mar 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.
    • 19 Dec 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top